Hala Raghib, BMedSc (Hons), PhD, MBA – Chief Executive Officer
Dr Hala Raghib is the CEO of Orpharma Pty Ltd. She has over 15 years experience in the healthcare and pharmaceutical industry with various roles held in Australian and multinational pathology services, medical devices and pharmaceuticals companies.
Hala has worked closely with companies in Australasia, Asia, the MENA region and Eastern Europe on generics, over-the-counter, medical devices and complementary medicines. She is an Ambassador for the Australian Museum Eureka Prizes.
Hala holds a Bachelor of Medical Science (Hons) and MBA from La Trobe University and PhD in pharmacology from RMIT University. She has been recognised with awards including Australian Museum Eureka Prize 2007 and La Trobe University Distinguished Young Achiever Award 2012. She was the inaugural MAWA Trust Doctorate scholarship recipient 2003-2007 and was listed as one of Melbourne’s Top 100 Most Powerful and Innovative Personalities in The Age Magazine 2007.
Ross Dobinson, BBus – Chairman
Ross has extensive corporate advisory and investment banking experience. He has taken an entrepreneurial role in the commercialisation of technologies in a range of fields, including: agricultural science, pharmaceuticals, environmentally-friendly packaging, medical devices, drug delivery technology and nutriceuticals.
Ross has held positions as a Director of the listed stockbroking firm of Jacksons Limited, Head of Corporate Advisory Services at the stockbroking firm operated by National Australia Bank Limited (A.C. Goode & Co. Ltd), Director of National Australia Corporate Advisory Limited, Chairman of Hexima Ltd, Director of TPI Enterprises Ltd and Director of Corporate Advisory of Dresdner Australia Proprietary Limited. Ross has a Bachelor of Business Degree from Queensland University of Technology. He is currently Managing Director of TSL Group, Chairman of Acrux Limited, Micronix Pty Ltd and Diagnotech Pty Ltd. He is also a Director of Horizon Science Pty Ltd, Origin Capital Limited and Healthfarm Fine Foods Pty Ltd.
Ross has taken two highly successful biotechnology companies from pre-seed stage to listed status with a current market capitalisation of over $1 billion.
In addition, the Management team core competencies include:
- Managing pathways to regulatory approvals in key markets
- Understanding of novel therapeutics & disease awareness
- Capacity to work with healthcare professionals and KOLs
- Scientific Affairs
- Negotiation of reimbursement schedules in key markets
- Tender participation
- Importation and distribution
- Business development & Commercialisation
- Portfolio management
- Patient Support Programs